Abstract Details

Title Association of Traumatic Brain Injury, Mild Cognitive Impairment and Dementia in the Framingham Heart Study’s Original Cohort

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) S39 - Neurobiology of Dementia (5:06 PM-5:18 PM)

Poster/Presentation
Number 009

Background

Research on the relationship between TBI, AD and AD related dementias is inconsistent.

Objective

To estimate the associations between traumatic brain injury (TBI), mild cognitive impairment (MCI), all-cause dementia, and Alzheimer’s disease (AD) dementia.

Design/Methods

The Framingham Heart Study (FHS) is a population-based cohort study which recruited its original cohort, ages 30-62, between 1948-1950. Information on TBIs was collected by self-report and comprehensive review of medical records obtained through FHS health history updates until death. TBI occurrence and severity were operationalized using modified American Congress of Rehabilitation Medicine and Veterans Affairs/Department of Defense criteria respectively. MCI, dementia, and AD dementia consensus diagnoses were operationalized using modified Peterson criteria, Diagnostic and Statistical Manual of Mental Disorders, 4^th edition, and National Institute of Neurological and Communicative Diseases and Stroke/AD and Related Disorders Association criteria respectively.

Results

The study included 715 participants with TBI and 2145 age- and sex-matched participants without TBI who were cognitively normal at time of TBI and followed for an average of 16±17 years. 567 (26.43%), 461 (21.49%) and 373 (17.39%) participants without TBI developed MCI, all cause dementia and AD dementia respectively compared with 271 (37.9%), 218 (30.49%) and 131 (21.12%) of those with TBI. For mild TBI, hazard ratios (HRs) for MCI, all-cause dementia and AD dementia were 1.55 (95%CI 1.14–2.12), 1.47 (95%CI 1.02-2.14), and 1.06 (95%CI 0.68-1.66) respectively. For moderate-to-severe TBI, HRs for MCI, all cause dementia and AD dementia were 3.50 (95%CI 1.10-11.17), 4.61 (95%CI 0.96-22.14), and 6.36 (95%CI 0.72-56.50) respectively.

Conclusions

In this cohort followed for more than a decade and comprehensively assessed for TBI and dementia-related outcomes, there were small to moderate sized associations of mild TBI and large associations of moderate-severe TBI with MCI and all-cause dementia. Association between mild TBI and dementia may be driven by non-AD etiologies.

Authors/Disclosures
Shruti S. Durape, MBBS, MPH (Boston University Chobanian & Avedisian School of Medicine) PRESENTER	Dr. Durape has nothing to disclose.
	No disclosure on file
	No disclosure on file
Kurtis Chien-Young	Mr. Chien-Young has received research support from the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number T35HL139444.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Douglas I. Katz, MD, FAAN (Boston Medical Center)	Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law firms. The institution of Dr. Katz has received research support from NINDS/NIH. Dr. Katz has received publishing royalties from a publication relating to health care.
Yorghos Tripodis	No disclosure on file
Michael Alosco, PhD (Boston University)	The institution of Michael Alosco, PHD has received research support from NIH.
Kristen Dams-O'Connor, PhD (Department of Rehabilitation Medicine & Department of Neurology)	Dr. Dams-O'Connor has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Dams-O'Connor has received research support from NIH. The institution of Dr. Dams-O'Connor has received research support from Department of Defense. The institution of Dr. Dams-O'Connor has received research support from National Institute on Disability Independent Living and Rehabilitation Research. The institution of Dr. Dams-O'Connor has received research support from Patient Reported Outcomes Research Institute.
Rhoda Au, PhD (Boston University School of Medicine)	Dr. Au has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovoNordisk. Dr. Au has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Au has received publishing royalties from a publication relating to health care. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with Davos Alzheimer's Collaborative. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with High Lantern.
Jesse B. Mez, MD (Boston University School of Medicine)	The institution of Dr. Mez has received research support from NIH, DOD.